788A8487-6A02-4BF5-8E84-16BE5D92BF0F
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 4.664914586070959
- age_years
- 76
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.575
- ALLOGRAFT_REJECTION+0.564
- IL6_JAK_STAT3_SIGNALING+0.553
- INTERFERON_ALPHA_RESPONSE+0.530
- TNFA_SIGNALING_VIA_NFKB+0.529
- MYC_TARGETS_V1+0.512
- ANGIOGENESIS+0.492
- DNA_REPAIR+0.483
- INFLAMMATORY_RESPONSE+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.449
Top 10 suppressed
- KRAS_SIGNALING_DN-0.384
- MITOTIC_SPINDLE-0.228
- SPERMATOGENESIS-0.203
- ESTROGEN_RESPONSE_EARLY-0.128
- BILE_ACID_METABOLISM-0.110
- WNT_BETA_CATENIN_SIGNALING-0.099
- MYOGENESIS-0.046
- APICAL_SURFACE-0.044
- PANCREAS_BETA_CELLS-0.042
- HEDGEHOG_SIGNALING-0.036
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 3027792F-79B6-4729-9452-C4A72A7C4686 | — | — | 0.978 |
| 2 | FFECD0E9-70C2-44BD-B0B4-E8C4B60B793A | — | — | 0.973 |
| 3 | F9A39954-57EB-4A3F-97A0-1801B08BBD53 | — | — | 0.971 |
| 4 | SRR934883 | — | — | 0.971 |
| 5 | 53B31ABD-AD68-4A44-A525-23FD413115D5 | — | — | 0.970 |
| 6 | 8DA59514-8B25-493E-B226-818F2521B5D5 | — | — | 0.967 |
| 7 | 665044AD-F2DD-43C2-BCDE-982A8F5C5830 | — | — | 0.966 |
| 8 | 3E499D12-B08A-491C-98C6-19EA420BDC99 | — | — | 0.965 |
| 9 | AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE | — | — | 0.963 |
| 10 | D8A3D7E7-BDC0-42FF-B451-E25F472E8612 | — | — | 0.963 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.575 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.564 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.553 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.529 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.512 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.492 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.483 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.449 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.447 | Inavolisib | — uncovered |
| HYPOXIA | 0.442 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.423 | Idelalisib | — uncovered |
| APOPTOSIS | 0.422 | Idelalisib | — uncovered |
| COMPLEMENT | 0.422 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.407 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.387 | Inavolisib | — uncovered |
| COAGULATION | 0.375 | Binimetinib | — uncovered |
| MTORC1_SIGNALING | 0.371 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.359 | Inavolisib | — uncovered |